Get the Stockscreener App
4.39
2.66%
-0.12
Minerva Neurosciences Inc stock is traded at $4.39, with a volume of 132.51K.
It is down -2.66% in the last 24 hours and down -15.74% over the past month.
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
See More
Previous Close:
$4.51
Open:
$4.61
24h Volume:
132.51K
Relative Volume:
0.58
Market Cap:
$204.52M
Revenue:
-
Net Income/Loss:
$-293.42M
P/E Ratio:
-0.1638
EPS:
-26.8031
Net Cash Flow:
$-13.51M
1W Performance:
-5.18%
1M Performance:
-15.74%
6M Performance:
+8.66%
1Y Performance:
+143.89%
1-Day Range:
$4.29
$4.7109
1-Week Range:
$4.29
$4.915
52-Week Range:
$1.566
$12.46
Minerva Neurosciences Inc Stock (NERV) Company Profile
Name
Minerva Neurosciences Inc
Sector
Industry
Phone
617-600-7373
Address
1500 DISTRICT AVENUE, BURLINGTON, MA
Compare NERV vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NERV
Minerva Neurosciences Inc
|
4.39 | 204.52M | 0 | -293.42M | -13.51M | -26.80 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Minerva Neurosciences Inc Stock (NERV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | Citizens | Mkt Outperform |
| Jun-08-20 | Reiterated | H.C. Wainwright | Buy |
| May-14-20 | Initiated | BTIG Research | Buy |
| Oct-02-19 | Reiterated | Chardan Capital Markets | Buy |
| Sep-25-19 | Initiated | Chardan Capital Markets | Buy |
| Sep-18-19 | Initiated | William Blair | Outperform |
| May-31-19 | Initiated | H.C. Wainwright | Buy |
| Sep-01-17 | Initiated | Citigroup | Buy |
| Mar-06-17 | Resumed | Jefferies | Buy |
| May-12-16 | Resumed | Jefferies | Buy |
View All
Minerva Neurosciences Inc Stock (NERV) Latest News
Minerva Neurosciences (NERV) Holds Near Support After Modest Decline: Key Levels in FocusMutual Fund Flow - newsline.com
Minerva Neurosciences (NERV) CFO awarded 680,000 stock options at $4.6800 - Stock Titan
Minerva Neurosciences (NERV) CEO granted 1.69M stock options at $4.68 strike - Stock Titan
Minerva Neurosciences (NERV) grants director 50,000 stock options at $4.68 - Stock Titan
Minerva Neurosciences (NERV) director receives stock options for 50,000 shares - Stock Titan
Minerva Neurosciences grants 50,000 options to director | NERV Insider Trading - Stock Titan
Minerva Neurosciences director granted 50,000 options | NERV Insider Trading - Stock Titan
Minerva Neurosciences (NERV) awards 50,000 stock options to director - Stock Titan
Minerva Neurosciences (NERV) loses 37.5% in 4 weeks, here's why a trend reversal may be around the corner - MSN
NERV: Roluperidone targets negative symptoms in schizophrenia, with pivotal data expected in 2027 - TradingView
Minerva Neurosciences Updates Governance Following 2026 Shareholder Meeting - TipRanks
Minerva Neurosciences (NERV) holders approve officer shield, drop forum clause - Stock Titan
NERV Q1 2026 Earnings: Wider-than-Expected Loss Highlights Ongoing Development CostsHealthcare Earnings Report - newsline.com
Minerva Neurosciences Establishes Scientific Advisory Board - GlobeNewswire
Minerva Neurosciences (NERV) Holds Near Support After Slight Decline: Key Levels to WatchSMA Signal - thelegaladvocate.com
Minerva Neurosciences Announces Sales Agreement with Leerink Partners for Common Stock Offering (Form 8-K Filing) - Minichart
Minerva Neurosciences (NERV) Edges Lower Near Support Level Amid Quiet TradingOBV Breakout - newsline.com
Minerva Neurosciences Launches ATM Offering to Fund Trial - TipRanks
Minerva Neurosciencesto offer and sell up to $75 million in common stock through Leerink Partners - marketscreener.com
Minerva Neurosciences (NERV) adds $75M ATM program and lengthens key Phase 3 C19 trial - Stock Titan
Minerva Neurosciences (NASDAQ: NERV) launches $75M at‑the‑market stock program - Stock Titan
Minerva Neurosciences Inc (NERV) Q1 2026 Earnings: Wider Loss Highlights Ongoing Pre-Revenue Development StageDownward Estimate Revision - Newser
Minerva Neurosciences Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Faces Challenges - Newser
All you need to know about Minerva Neurosciences (NERV) rating upgrade to buy - MSN
Minerva Neurosciences Q1 2026 Earnings: EPS Misses Street Estimates, Stock Gains on Pipeline OptimismPost-Earnings Drift - Newser
All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy - Yahoo Finance
Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference - Investing News Network
Minerva CEO to join Jefferies 2026 healthcare fireside chat June 4 - Stock Titan
Minerva Neurosciences (NERV) Slides -5.22% as Selling Pressure Mounts 2026-05-15Popular Market Picks - Newser
Janus Henderson (NERV) reports 4.3M shares, 9.9% stake disclosed - Stock Titan
Balyasny group (NASDAQ: NERV) discloses a 9.99% stake of 4.32M shares - Stock Titan
TradingKey - TradingKey
Minerva Neurosciences (NERV) Slips -0.90%, Testing $5.22 Support 2026-05-14Dip Buy Trade - The Legal Advocate
H.C. Wainwright Maintains Minerva Neurosciences(NERV.US) With Hold Rating, Raises Target Price to $7 - Moomoo
8-K: Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updatesmoomoo - Moomoo
Minerva Neurosciences, Inc. 1Q 2026: Revenue $0 Net loss $(125.4M), EPS $(2.86) — 10-Q Summary - TradingView
Minerva Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Minerva Neurosciences (NERV) posts large Q1 2026 non-cash loss but keeps cash runway - Stock Titan
Minerva Neurosciences Posts 1Q $109.4M Non-Cash Expense For Change in Fair Value of Warrant Liability, Losses Recognized Upon Exercise of Warrants - Moomoo
Phase 3 roluperidone trial and larger Q1 loss at Minerva (NERV) - Stock Titan
Minerva Neurosciences: Q1 Earnings Snapshot - marketscreener.com
No approved drug targets these schizophrenia symptoms; Phase 3 starts - Stock Titan
Press Release: Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates - Moomoo
Minerva Neurosciences, Inc (NASDAQ:NERV) Short Interest Update - MarketBeat
Minerva launched with new outperform at Citizens on schizophrenia candidate - MSN
Minerva Neurosciences (NERV) price target increased by 31.03% to 9.69 - MSN
Minerva Neurosciences | 8-K: Current report - Moomoo
NERV SEC FilingsMinerva Neurosci 10-K, 10-Q, 8-K Forms - Stock Titan
[ARS] Minerva Neurosciences, Inc. SEC Filing - Stock Titan
Officer liability and pay votes at Minerva Neurosciences (NASDAQ: NERV) 2026 meeting - Stock Titan
Minerva Neurosciences Inc Stock (NERV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):